Long-term experience with pravastatin in clinical research trials.
ME McGovern, MJ Mellies - Clinical therapeutics, 1993 - europepmc.org
Pravastatin is a new lipid-lowering drug belonging to the class of 3-hydroxy-3-methylglutaryl
CoA (HMG-CoA) reductase inhibitors. Since 1986, more than 15,000 patients have received …
CoA (HMG-CoA) reductase inhibitors. Since 1986, more than 15,000 patients have received …
Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril
MC Kowala, M Valentine, R Recce… - Journal of …, 1998 - journals.lww.com
Abstract Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase and
angiotensin-converting enzyme (ACE) reduce experimental atherosclerosis by different …
angiotensin-converting enzyme (ACE) reduce experimental atherosclerosis by different …
Statins and inflammation
M Satny, JA Hubacek, M Vrablik - Current atherosclerosis reports, 2021 - Springer
Abstract Purpose of Review Chronic inflammation has been recognized as one of the most
important pathophysiological mechanisms' initiation and progression of atherosclerosis …
important pathophysiological mechanisms' initiation and progression of atherosclerosis …
Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia
BHR Wolffenbuttel, G Mahla, D Muller, A Pentrup… - The Netherlands journal …, 1998 - Elsevier
Background: High levels of total and LDL-cholesterol are associated with an increased risk
of atherosclerotic vascular disease. Lowering of serum cholesterol levels by pharmacologic …
of atherosclerotic vascular disease. Lowering of serum cholesterol levels by pharmacologic …
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors
M Takemoto, JK Liao - Arteriosclerosis, thrombosis, and vascular …, 2001 - Am Heart Assoc
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins are potent
inhibitors of cholesterol biosynthesis. Several large clinical trials have demonstrated the …
inhibitors of cholesterol biosynthesis. Several large clinical trials have demonstrated the …
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
JE Deanfield, P Sellier, E Thaulow, J Bultas… - European heart …, 2010 - academic.oup.com
Abstract Aims The DoUble-blind Atorvastatin AmLodipine (DUAAL) trial investigated
whether atorvastatin decreases ischaemia by a vascular benefit, independent of low-density …
whether atorvastatin decreases ischaemia by a vascular benefit, independent of low-density …
Dose–response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies
AS Wierzbicki, DP Mikhailidis - International journal of cardiology, 2002 - Elsevier
Epidemiological evidence and clinical trials with fibrate therapy show a clear relationship
between low levels of high-density lipoprotein cholesterol (HDL-C) and cardiovascular risk …
between low levels of high-density lipoprotein cholesterol (HDL-C) and cardiovascular risk …
Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin
RP Naoumova, S Dunn, L Rallidis, O Abu-Muhana… - Journal of lipid …, 1997 - ASBMB
HMG-CoA reductase inhibitors or statins are effective in both the primary and secondary
prevention of coronary heart disease, the extent of benefit being proportional to the …
prevention of coronary heart disease, the extent of benefit being proportional to the …
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives
M Devabhaktuni, S Bangalore - Vascular health and risk …, 2009 - Taylor & Francis
Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular
risk factors which together cause an increase in coronary heart disease-related events that …
risk factors which together cause an increase in coronary heart disease-related events that …
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease
JF Dorval, T Anderson, J Buithieu, S Chan… - The American journal of …, 2005 - Elsevier
The effects of combined atorvastatin and amlodipine on blood pressure (BP) and low-
density lipoprotein (LDL) cholesterol levels were investigated in 134 patients with …
density lipoprotein (LDL) cholesterol levels were investigated in 134 patients with …